Credit Suisse and Deutsche Bank were joint bookrunning managers
By Devika Patel
Knoxville, Tenn., Nov. 26 - Evogene Ltd. said the underwriters for its initial public offering of stock opted to exercise the deal's $11.06 million greenshoe in full, lifting total proceeds to $84.81 million. The deal was announced Nov. 6 and priced for $73.75 million with the greenshoe on Nov. 21.
The company sold 5.75 million ordinary shares at $14.75 per share. Of the shares, 750,000 were part of the fully exercised greenshoe.
Credit Suisse Securities and Deutsche Bank Securities were the joint bookrunning managers.
Proceeds will be used to develop and expand the company's ag-chemical operations and develop and commercialize its Evofuel activities.
The plant genomics company is based in Rehovot, Israel. It intends to list its stock on the New York Stock Exchange under the symbol "EVGN."
| Issuer: | Evogene Ltd.
|
| Issue: | Ordinary stock
|
| Amount: | $84,812,500 (including $11,062,500 greenshoe)
|
| Shares: | 5.75 million
|
| Price: | $14.75
|
| Warrants: | No
|
| Bookrunners: | Credit Suisse Securities and Deutsche Bank Securities
|
| Co-managers: | Oppenheimer & Co. and Piper Jaffray & Co.
|
| Announcement date: | Nov. 6
|
| Pricing date: | Nov. 21
|
| Settlement date: | Nov. 26
|
| Stock exchange: | NYSE: EVGN
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
